MÆDICA - a Journal of Clinical Medicine Logo
  • Home
  • Profile
  • Standards
    • Types of articles
    • Instructions for authors
    • Editing rules (peer-review protocol)
    • Official Journal’s protocols
  • Editorial Council
  • Peer-review TEAM
  • How to
  • Menu

Author archives

  • About
  • Latest Posts

Daniel CORIU

Latest posts by Daniel CORIU (see all)

  • Inherited Thrombophilia in Pregnant Women with Intrauterine Growth Restriction - June 18, 2015

Articles signed on MÆDICA, JCM:

Inherited Thrombophilia in Pregnant Women with Intrauterine Growth Restriction

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 9, nr. 4, 2014

CNCSIS - CMR - B+ OBBCSSR

Inherited Thrombophilia in Pregnant Women with Intrauterine Growth Restriction

Letitia CORIU, Elena COPACIU, Dan TULBURE, Rodica TALMACI, Diana SECARA, Daniel CORIU and Monica CIRSTOIU

ABSTRACT

Background: Intrauterine growth restriction (IUGR) is a major cause of fetal morbidity and mortality during pregnancy. The role of mutation in the factor V gene, prothrombin gene, MTHFR gene, as risk factors for intrauterine growth restriction during pregnancy, is not very well known so far.

Materials and methods: This is a retrospective study of 151 pregnant women with a history of complicated pregnancy: intrauterine growth restriction, preeclampsia, recurrent pregnancy loss or maternal venous thromboembolism, who were admitted in Bucharest Emergency University Hospital, during the period January 2010 to July 2014. Genetic testing was performed for all the cases to detect: factor V Leiden mutation, G20210A mutation in the prothrombin gene, C677T mutation and A1298C mutation in methylenetetrahydrofolate reductase (MTHFR) gene. Blood samples were obtained as soon as the diagnosis of intrauterine growth restriction was established with ultrasonography.

Results: The following gene mutations were associated with increased risk of IUGR: G20210A prothrombin gene mutation (OR 4.81, 95% CI 1.05 - 2.22, p= 0.043), G1691A factor V gene mutation (factor V Leiden) (OR 1.58, 95% CI 0.61 - 4.080, p= 0.347), C677T MTHFR gene mutation (OR 1.61, 95% CI 0.79 to 3.26, p= 0.186), compound heterozygous MTHFR C677T and A1298C (OR 1.66, 95% CI 0.81- 3.42, p= 0.169). Particularly, for G20210A prothrombin gene mutation we found statistically significant risk (p0.05) of IUGR.

Full text | PDF



plic-mail[email protected]

 Terms and conditions

© MÆDICA - a Journal of Clinical Medicine - All rights reserved